Although the U.S. stock market performed strongly in 2025, the share prices of South Korean e-commerce giant Coupang (CPNG) and U.S. health insurance company Oscar Health (OSCR) have remained largely flat. These two companies, operating in entirely different industries, have both chosen to sacrifice short-term profits for long-term growth space. As key strategic initiatives enter a harvest period in 2026, their stock prices possess significant potential for recovery and growth.
Coupang: Profit Inflection Point and Ecosystem Expansion
As the leading e-commerce platform in South Korea, Coupang has built a powerful moat centered around ultra-fast delivery. Its domestic South Korean business is highly profitable, with an adjusted profit margin of 8.8% last quarter. However, profit growth has stagnated in recent years, primarily due to strategic investments for long-term growth: on one hand, the company is entering the new market of Taiwan; on the other hand, it continues to expand into adjacent businesses like food delivery, fashion, and fintech, while heavily investing in AI chips and potential cloud services.
The core catalysts for 2026 lie in margin expansion and valuation re-rating. As the initial investment peak for new markets and businesses passes, its massive revenue base ($34 billion over the past 12 months) could significantly unleash profit elasticity if overall profitability improves. Coupang’s current market capitalization of approximately $42 billion is not particularly high relative to its revenue scale and dominant position in South Korea. Once the company can demonstrate its cross-regional, cross-business synergy capabilities and deliver on profit growth, the market will reassess its long-term value.
Oscar Health: Validating Pricing Power and Absorbing Regulatory Shocks
Oscar Health is a modern health insurer focused on the Affordable Care Act (Obamacare) marketplace. Driven by technology and a positive customer experience, it already serves 2 million members. The stock price faced pressure in 2025 due to industry-wide rising claims costs and the definite expiration of a key federal premium subsidy on January 1, 2026.
The turnaround in 2026 will depend on the effectiveness of its price increase strategy and the clarity of its growth path. To address cost pressures, the company has significantly raised premiums for its 2026 policies. If this move successfully helps drive the profit margin back to management’s target of around 5%, its operating profit could reach approximately $500 million based on the current annual revenue scale of $11.3 billion.
Meanwhile, although the subsidy expiration may lead to short-term customer attrition, in the long run, healthcare cost inflation grants the company sustained pricing power. The narrative of capturing market share from traditional insurers through its experience advantage remains valid. If it can stabilize revenue and achieve profitability by offsetting volume with price, its current market cap of just $4 billion would appear highly attractive.
Common Logic: Transitioning from the Investment Phase to the Harvest Phase
The core commonality between the two companies is that the current market pricing primarily reflects their short-term profit sacrifice and uncertainties, while underestimating the potential for profit recovery following adjustments to their business models.
For Coupang, the market awaits proof of return on its cross-sector investments; for Oscar Health, the market worries about regulatory changes impacting its growth. In 2026, both are expected to reach critical validation points for their fundamentals—Coupang’s profit margin inflection point and Oscar Health’s profit rebound. Investors should closely monitor how these companies deliver on these key catalysts in their quarterly earnings reports throughout 2026.
